
About
Authera is a pre-clinical biotechnology company focused on developing novel therapeutic biologics. It was founded in 2022 as a spin-off from Oslo University Hospital and the University of Oslo, and it works with academic institutions, non-profit organizations, life science investment firms, biotech companies, and pharmaceutical partners.
Services
Molecular design
Design of novel therapeutic molecules with tailored FcRn binding and transport properties.
Protein engineering studies
Comprehensive studies exploring protein engineering strategies for biologics.
Biochemical assays
Biochemical assays used to understand how candidates engage FcRn.
Cellular assays
Cell-based assays used to study intracellular sorting and FcRn-related properties.
In vivo mouse models
Mouse model studies to reveal pharmacokinetic profiles of novel therapeutic candidates.
Advanced biochemical assays
Uses biochemical assays to study how therapeutic candidates engage FcRn.
In vivo mouse model studies
Uses mouse models to assess pharmacokinetic profiles of novel therapeutic candidates.
Capabilities
- Assays and studies
- Antibodies
- PK/PD
- In vivo
- Rodent models
- Biochemical assays
- Cellular assays
- Therapeutic areas
- Exudative eye diseases
Modalities and species
- Modalities
- Antibody
- Species and models
- Mouse models
- FcRn
- Mouse
Industries served
- Biotech
- Pharmaceutical
Details
- Founded
- 2022
- Based in
- Oslo, Norway